Authors
Latest:
Samer Srour, MB ChB, MS, on Improving CAR T-Cell Therapy for Solid TumorsThe assistant professor of stem cell transplantation at MD Anderson Cancer Center discussed positive data in ccRCC that he believes should excite the solid tumor field as a whole.
Latest:
Advantages of Manufacturing Cell Therapies In-HouseThe chief technology and chief executive officer of Mustang Bio discussed the company’s integrated approach to drug development.
Latest:
Mustafa Turkoz, PhD, on Rejuvenating Immune Cells With ERA ReprogrammingThe head of immunology at Turn Biotechnologies discussed preclinical data demonstrating proof-of-concept with the company’s epigenome reprogramming platform.
Latest:
Gene Therapy for Sickle Cell DiseaseExperts discuss the safety profile and cost of gene therapy for the management of sickle cell disease.
Latest:
Mary “Nora” Disis, MD, on Reevaluating the Potential of CAR-T Approaches in Ovarian CancerThe director of University of Washington Medicine’s Cancer Vaccine institute discussed the importance of continuing to develop new CAR-T approaches in the ovarian cancer field despite initial setbacks.
Latest:
Electrotransfection: A Different Approach to Plasmid DeliveryThe chief scientific officer and chief medical officer at Eyevensys discuss the biotech company's pipeline and approach to gene therapy.
Latest:
Sebastian Michels, MD, on the Role of Alternative Polyadenylation in ALS Disease PathogenesisThe postdoctoral fellow and member of the La Spada Lab at University of California, Irvine, discussed findings he presented at ANA’s 2023 conference that may have implications for future RNA therapy development.
Latest:
Improving Speed and Fidelity of CRISPR/Cas9: Kenneth Johnson, PhD, and David Taylor, PhDThe professors and researchers from The University of Texas at Austin discussed new findings of Cas9 structure and mechanisms.
Latest:
Working With the Community to Improve Patient Access to Trials, TherapiesRob Richards, administrative director, cell therapy and transplant, University of Pennsylvania, discussed improving reach of gene therapy trials and therapies.
Latest:
Expediting the Development of Patient-Specific iSPC Cell TherapiesStefan Braam, PhD, chief executive officer of Ncardia and Cellistic discussed the companies’ work in the cell therapy space.
Latest:
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s GrowthThe clinical professor of neurology and pediatrics at Keck School of Medicine of USC also discussed current strategies with gene therapy administration.
Latest:
Helping to Bring Preclinical Gene Therapy Research to First-in-Human TrialsRoger Hajjar, MD, the director of the Mass General Brigham Gene and Cell Therapy Institute, also discussed the Institute’s presentations at ASGCT’s 2025 conference.
Latest:
Using a Digital App to Aid Caregivers for Patients Undergoing Hematopoietic Stem Cell TransplantJamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center, discussed her presentation at ASCO this year.
Latest:
Susan Bal, MD, on Promising Efficacy With GPRC5D-CAR Therapy in R/R Multiple MyelomaThe assistant professor of medicine at University of Alabama – Birmingham discussed efficacy findings on BMS-986983 and more research to be done.
Latest:
NK Cell Therapy Potential in Treating COVID-19 and Other VirusesAllen Feng, PhD, chief scientific officer, HebeCell, discussed the company’s NK cell technologies.
Latest:
The Future of Gene Therapies in Inherited Retinal DiseasesMariya Moosajee, MBBS, BSc, PhD, FRCOphth, discussed the next generation of gene therapy for inherited retinal diseases.
Latest:
Improving Cell and Gene Therapy with Innovative Nonviral Delivery VectorsAn overview of novel drug-delivery vehicles and their potential role in improving gene and cell therapies.
Latest:
Challenges in R/R LBC Lymphoma After CAR T TherapyJulio Chavez, MD, MD, discussed treatment options for LBCL after relapsing on CAR T-cell therapy.
Latest:
Christine Coughlin, MD, PhD, on TRACK-NK Technology in Non-Small Cell Lung CancerThe chief executive officer of Cytoimmune discussed the company’s technology platforms and programs.
Latest:
Steven Katz, MD, on Assessing New Delivery Methods for CAR T-Cell TherapyThe chief medical officer of Trisalus Life Sciences discussed studies evaluating the company’s PEDD system.
Latest:
Bringing Autologous Natural Killer Cell Therapy to Parkinson DiseasePaul Y. Song, MD, the chairman and chief executive officer of NKGen, discussed discussed the new clinical study design for evaluating cell therapy SNK01 in PD.
Latest:
David Sallman, MD, on Updates From the AMELI-01 Trial of UCART123v1.2 for AMLThe assistant member of the department of malignant hematology at Moffitt Cancer Center discussed updated data on the allogeneic CAR T therapy, UNICART123v1.2.
Latest:
The Safety Profile of J&J's CD19/CD20-Targeted CAR-T Therapy JNJ-90014496 in R/R LBCLMatthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital, discussed data from a phase 1b trial.
Latest:
CAR T: A Novel Approach for Mantle Cell LymphomaNew treatment options expand management of relapsed or refractory disease.
Latest:
Keys to a Successful Cell and Gene Therapy LaunchThe success of cell and gene therapies relies not just on approvability but on affordability and accessibility. Innovative manufacturing, automation, and digital tools are key to expanding patient access and ensuring commercial viability.
Latest:
Rebecca Epperly, MD, on Research Considerations as CAR-T Therapy Comes of AgeThe clinical investigator in the Department of Bone Marrow Transplantation & Cellular Therapy at St. Jude Children’s Research Hospital discussed several areas of interest for research now that CAR-T is here to stay.
Latest:
Treating Solid Tumors With Personalized Immunotherapy: Julian Molina, MD, PhDThe hematologist/oncologist from Mayo Clinic discussed targeting HLA loss in solid tumors.
Latest:
Alexis Kuhn, PharmD, BCOP, on Hemoglobinopathy Gene Therapies From a Pharmacist’s PerspectiveThe pediatric oncology pharmacist at Mayo Clinic discussed the incorporation of the recently FDA-approved gene therapies for SCD and TDT into the work of pharmacists.
Latest:
Laurent Poirot, PhD, on the FDA’s IND Clearance for UCART20x22The senior vice president of immunology at Cellectis discussed the company’s investigational dual-targeted CAR-T therapy for B-cell malignancies.
